Research programme: SCC-S2 targeted anticancer therapeutics - Insys Therapeutics
Latest Information Update: 19 Oct 2016
At a glance
- Originator Georgetown University; NeoPharm Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 10 Dec 2001 New profile
- 10 Dec 2001 Preclinical development for Solid tumours in USA (unspecified route)